Buruli ulcer (Mycobacterium ulcerans infection)

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 102, Issue 10, 2008, Pages 969-978

  Walsh, Douglas S ^a   Portaels, Françoise ^b   Meyers, Wayne M ^c  

^a U S ARMY   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Buruli ulcer; Emerging diseases; Infection; Mycobacteria; Mycobacterium ulcerans; Review

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; BCG VACCINE; CIPROFLOXACIN; MYCOLACTONE; POLYKETIDE SYNTHASE; RIFAMPICIN; STREPTOMYCIN;

AFRICA; AGRICULTURE; BACTERIUM CULTURE; BONE DESTRUCTION; BURULI ULCER; CLINICAL FEATURE; DEFORESTATION; DISEASE TRANSMISSION; DRUG WITHDRAWAL; ENDEMIC DISEASE; ENVIRONMENTAL FACTOR; HEARING IMPAIRMENT; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHERMIC THERAPY; INCIDENCE; INFECTION RISK; JAUNDICE; KELOID; KIDNEY FAILURE; MYCOBACTERIUM ULCERANS; NONHUMAN; NYSTAGMUS; OSTEITIS; OSTEOMYELITIS; PATHOGENESIS; PHYSIOTHERAPY; REVIEW; SKIN INJURY; SKIN TRANSPLANTATION; VERTIGO; WETLAND;

ADOLESCENT; AFRICA; BURULI ULCER; CHILD; FEMALE; HUMANS; MALE; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS;

CORYNEBACTERINEAE; MYCOBACTERIUM ULCERANS;

EID: 50549100387     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2008.06.006     Document Type: Review

References (79)

1. Ablordey A., Kotlowski R., Swings J., and Portaels F. PCR amplification with primers based on IS2404 and GC-rich repeated sequence reveals polymorphism in Mycobacterium ulcerans. J. Clin. Microbiol. 43 (2005) 448-451
2. Addo P., Owusu E., Adu-Addai B., Quartey M., Abbas M., Dodoo A., and Ofori-Adjei D. Findings from a buruli ulcer mouse model study. Ghana Med. J. 39 (2005) 86-93
3. Adusumilli S., Mve-Obiang A., Sparer T., Meyers W., Hayman J., and Small P.L. Mycobacterium ulcerans toxic macrolide, mycolactone, modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell. Microbiol. 7 (2005) 1295-1304
4. Aguiar J., and Steunou C. Buruli ulcers in rural areas of Benin: management of 635 cases. Med. Trop. (Mars). 57 (1997) 83-90 [in French]
5. Asiedu K., and Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am. J. Trop. Med. Hyg. 59 (1998) 1015-1022
6. Aujoulat I., Johnson C., Zinsou C., Guedenon A., and Portaels F. Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop. Med. Int. Health 8 (2003) 750-759
7. Chauty A., Ardant M.F., Adeye A., Euverte H., Guedenon A., Johnson C., Aubry J., Nuermberger E., and Grosset J. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51 (2007) 4029-4035
8. Coloma J.N., Navarrete-Franco G., Iribe P., and Lopez-Cepeda L.D. Ulcerative cutaneous mycobacteriosis due to Mycobacterium ulcerans: report of two Mexican cases. Int. J. Lepr. Other Mycobact. Dis. 73 (2005) 5-12
9. Coutanceau E., Marsollier L., Brosch R., Perret E., Goossens P., Tanguy M., Cole S.T., Small P.L., and Demangel C. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell. Microbiol. 7 (2005) 1187-1196
10. Daffe M., Varnerot A., and Levy-Frebault V.V. The phenolic mycoside of Mycobacterium ulcerans: structure and taxonomic implications. J. Gen. Microbiol. 138 (1992) 131-137
11. Debacker M., Zinsou C., Aguiar J., Meyers W.M., and Portaels F. First case of Mycobacterium ulcerans disease (Buruli ulcer) following a human bite. Clin. Infect. Dis. 36 (2003) e67-68
12. Debacker M., Aguiar J., Steunou C., Zinsou C., Meyers W.M., Guedenon A., Scott J.T., Dramaix M., and Portaels F. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg. Infect. Dis. 10 (2004) 1391-1398
13. Debacker M., Aguiar J., Steunou C., Zinsou C., Meyers W.M., Scott J.T., Dramaix M., and Portaels F. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop. Med. Int. Health 9 (2004) 1297-1304
14. Debacker M., Aguiar J., Steunou C., Zinsou C., Meyers W.M., and Portaels F. Buruli ulcer recurrence, Benin. Emerg. Infect. Dis. 11 (2005) 584-589
15. Dodge O.G. Mycobacterial skin ulcers in Uganda: histopathological and experimental aspects. J. Pathol. Bacteriol. 88 (1964) 167-174
16. Dodge O.G., and Lunn H.F. Buruli ulcer: a mycobacterial skin ulcer in a Ugandan child. J. Trop. Med. Hyg. 65 (1962) 139-142
17. Duker A.A., Portaels F., and Hale M. Pathways of Mycobacterium ulcerans infection: a review. Environ. Int. 32 (2006) 567-573
18. Eddyani M., Debacker M., Martin A., Aguiar J., Johnson C.R., Uwizeye C., Fissette K., and Portaels F. Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J. Clin. Microbiol. 46 (2008) 69-72
19. En J., Goto M., Nakanaga K., Higashi M., Ishii N., Saito H., Yonezawa S., Hamada H., and Small P.L. Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study. Infect. Immun. 76 (2008) 2002-2007
20. Evans M.R., Mawdsley J., Bull R., Lockwood D.N., Thangaraj H., Shanahan D., and Rajakulasingam K. Buruli ulcer in a visitor to London. Br. J. Dermatol. 149 (2003) 907-909
21. Faber W.R., Arias-Bouda L.M., Zeegelaar J.E., Kolk A.H., Fonteyne P.A., Toonstra J., and Portaels F. First reported case of Mycobacterium ulcerans infection in a patient from China. Trans. R. Soc. Trop. Med. Hyg. 94 (2000) 277-279
22. George K.M., Chatterjee D., Gunawardana G., Welty D., Hayman J., Lee R., and Small P.L. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283 (1999) 854-857
23. Guarner J., Bartlett J., Whitney E.A., Raghunathan P.L., Stienstra Y., Asamoa K., Etuaful S., Klutse E., Quarshie E., van der Werf T.S., van der Graaf W.T., King C.H., and Ashford D.A. Histopathologic features of Mycobacterium ulcerans infection. Emerg. Infect. Dis. 9 (2003) 651-656
24. Guerra H., Palomino J.C., Falconi E., Bravo F., Donaires N., Van Marck E., and Portaels F. Mycobacterium ulcerans Disease, Peru. Emerg. Infect. Dis. 14 (2008) 373-377
25. Johnson R.C., Ifebe D., Hans-Moevi A., Kestens L., Houessou R., Guedenon A., Meyers W.M., and Portaels F. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS 16 (2002) 1704-1705
26. Johnson P.D., Azuolas J., Lavender C.J., Wishart E., Stinear T.P., Hayman J.A., Brown L., Jenkin G.A., and Fyfe J.A. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg. Infect. Dis. 13 (2007) 1653-1660
27. Johnson R.C., Nackers F., Glynn J.R., de Biurrun Bakedano E., Zinsou C., Aguiar J., Tonglet R., and Portaels F. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 22 (2008) 901-903
28. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348 (1996) 17-24
29. Kiszewski A.E., Becerril E., Aguilar L.D., Kader I.T., Meyers W., Portaels F., and Hernandez Pando R. The local immune response in ulcerative lesions of Buruli disease. Clin. Exp. Immunol. 143 (2006) 445-451
30. Krieg R.E., Hockmeyer W.T., and Connor D.H. Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Arch. Dermatol. 110 (1974) 783-788
31. MacCallum P., Tolhurst J.C., Buckle G., and Sissons H.A. A new mycobacterial infection in man. J. Pathol. Bacteriol. 60 (1948) 93-122
32. Marsollier L., Robert R., Aubry J., Saint Andre J.P., Kouakou H., Legras P., Manceau A.L., Mahaza C., and Carbonnelle B. Aquatic insects as a vector for Mycobacterium ulcerans. Appl. Environ. Microbiol. 68 (2002) 4623-4628
33. Marsollier L., Aubry J., Coutanceau E., Andre J.P., Small P.L., Milon G., Legras P., Guadagnini S., Carbonnelle B., and Cole S.T. Colonization of the salivary glands of Naucoris cimicoides by Mycobacterium ulcerans requires host plasmatocytes and a macrolide toxin, mycolactone. Cell. Microbiol. 7 (2005) 935-943
34. Marsollier L., Brodin P., Jackson M., Kordulakova J., Tafelmeyer P., Carbonnelle E., Aubry J., Milon G., Legras P., Andre J.P., Leroy C., Cottin J., Guillou M.L., Reysset G., and Cole S.T. Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog. 3 (2007) e62
35. Marston B.J., Diallo M.O., Horsburgh Jr. C.R., Diomande I., Saki M.Z., Kanga J.M., Patrice G., Lipman H.B., Ostroff S.M., and Good R.C. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am. J. Trop. Med. Hyg. 52 (1995) 219-224
36. Meyers W.M. Mycobacterial infections of the skin. In: Doerr W., and Seifert G. (Eds). Tropical Pathology (1995), Springer-Verlag, Berlin
37. Meyers W.M., Shelly W.M., and Connor D.H. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am. J. Trop. Med. Hyg. 23 (1974) 924-929
38. Meyers W.M., Shelly W.M., Connor D.H., and Meyers E.K. Human Mycobacterium ulcerans infections developing at sites of trauma to skin. Am. J. Trop. Med. Hyg. 23 (1974) 919-923
39. Meyers W.M., Tignokpa N., Priuli G.B., and Portaels F. Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in Togo. Br. J. Dermatol. 134 (1996) 1116-1121
40. Mve-Obiang A., Lee R.E., Portaels F., and Small P.L. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect. Immun. 71 (2003) 774-783
41. Nackers F., Johnson R.C., Glynn J.R., Zinsou C., Tonglet R., and Portaels F. Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli Ulcer) in Benin. Am. J. Trop. Med. Hyg. 77 (2007) 834-836
42. Nakanaga K., Ishii N., Suzuki K., Tanigawa K., Goto M., Okabe T., Imada H., Kodama A., Iwamoto T., Takahashi H., and Saito H. Mycobacterium ulcerans subsp. shinshuense" isolated from a skin ulcer lesion: identification based on 16S rRNA gene sequencing. J. Clin. Microbiol. 45 (2007) 3840-3843
43. O'Brien D.P., Hughes A.J., Cheng A.C., Henry M.J., Callan P., McDonald A., Holten I., Birrell M., Sowerby J.M., Johnson P.D., and Athan E. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med. J. Aust. 186 (2007) 58-61
44. Pahlevan A.A., Wright D.J., Andrews C., George K.M., Small P.L., and Foxwell B.M. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J. Immunol. 163 (1999) 3928-3935
45. Phanzu D.M., Bafende E.A., Dunda B.K., Imposo D.B., Kibadi A.K., Nsiangana S.Z., Singa J.N., Meyers W.M., Suykerbuyk P., and Portaels F. Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am. J. Trop. Med. Hyg. 75 (2006) 311-314
46. Pimsler M., Sponsler T.A., and Meyers W.M. Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. J. Infect. Dis. 157 (1988) 577-580
47. Portaels F., Fonteyne P.A., de Beenhouwer H., de Rijk P., Guedenon A., Hayman J., and Meyers W.M. Variability in 3′ end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates. J. Clin. Microbiol. 34 (1996) 962-965
48. Portaels F., Elsen P., Guimares-Peres A., Fonteyne P.-L., and Meyers W.M. Insects in the transmission of Mycobacterium ulcerans. Lancet 353 (1999) 986
49. Portaels F., Chemlal K., Elsen P., Johnson P.D., Hayman J.A., Hibble J., Kirkwood R., and Meyers W.M. Mycobacterium ulcerans in wild animals. Rev. Sci. Tech. 20 (2001) 252-264
50. Portaels F., Aguiar J., Debacker M., Guedenon A., Steunou C., Zinsou C., and Meyers W.M. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect. Immun. 72 (2004) 62-65
51. Portaels F., Meyers W.M., Ablordey A., Castro A.G., Chemlal K., de Rijk P., Elsen P., Fissette K., Fraga A.G., Lee R., Mahrous E., Small P.L., Stragier P., Torrado E., Van Aerde A., Silva M.T., and Pedrosa J. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl. Trop. Dis. 2 (2008) e178
52. Pouillot R., Matias G., Wondje C.M., Portaels F., Valin N., Ngos F., Njikap A., Marsollier L., Fontanet A., and Eyangoh S. Risk factors for buruli ulcer: a case control study in Cameroon. PLoS Negl. Trop. Dis. 1 (2007) e101
53. Pszolla N., Sarkar M.R., Strecker W., Kern P., Kinzl L., Meyers W.M., and Portaels F. Buruli ulcer: a systemic disease. Clin. Infect. Dis. 37 (2003) e78-82
54. Quek T.Y., Athan E., Henry M.J., Pasco J.A., Redden-Hoare J., Hughes A., and Johnson P.D. Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg. Infect. Dis. 13 (2007) 1661-1666
55. Read J.K., Heggie C.M., Meyers W.M., and Connor D.H. Cytotoxic activity of Mycobacterium ulcerans. Infect. Immun. 9 (1974) 1114-1122
56. Revill W.D.L., and Barker D.J.P. Seasonal distribution of mycobacterial skin ulcers. Br. J. Prev. Soc. Med. 26 (1972) 23-27
57. Rondini S., Mensah-Quainoo E., Troll H., Bodmer T., and Pluschke G. Development and application of real-time PCR assay for quantification of Mycobacterium ulcerans DNA. J. Clin. Microbiol. 41 (2003) 4231-4237
58. Ross B.C., Johnson P.D., Oppedisano F., Marino L., Sievers A., Stinear T., Hayman J.A., Veitch M.G., and Robins-Browne R.M. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl. Environ. Microbiol. 63 (1997) 4135-4138
59. Schutte D., Um-Boock A., Mensah-Quainoo E., Itin P., Schmid P., and Pluschke G. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl. Trop. Dis. 1 (2007) e2
60. Siegmund V., Adjei O., Racz P., Berberich C., Klutse E., van Vloten F., Kruppa T., Fleischer B., and Bretzel G. Dry-reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed Mycobacterium ulcerans-associated disease in areas in the tropics where M. ulcerans is endemic. J. Clin. Microbiol. 43 (2005) 271-276
61. Stienstra Y., van der Werf T.S., Oosterom E., Nolte I.M., van der Graaf W.T., Etuaful S., Raghunathan P.L., Whitney E.A., Ampadu E.O., Asamoa K., Klutse E.Y., Te Meerman G.J., Tappero J.W., Ashford D.A., and van der Steege G. Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun. 7 (2006) 185-189
62. Stinear T., Ross B.C., Davies J.K., Marino L., Robins-Browne R.M., Oppedisano F., Sievers A., and Johnson P.D. Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J. Clin. Microbiol. 37 (1999) 1018-1023
63. Stinear T., Davies J.K., Jenkin G.A., Hayman J.A., Oppedisano F., and Johnson P.D. Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl. Environ. Microbiol. 66 (2000) 3206-3213
64. Stinear T.P., Mve-Obiang A., Small P.L., Frigui W., Pryor M.J., Brosch R., Jenkin G.A., Johnson P.D., Davies J.K., Lee R.E., Adusumilli S., Garnier T., Haydock S.F., Leadlay P.F., and Cole S.T. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc. Natl. Acad. Sci. USA 101 (2004) 1345-1349
65. Stragier P., Ablordey A., Bayonne L.M., Lugor Y.L., Sindani I.S., Suykerbuyk P., Wabinga H., Meyers W.M., and Portaels F. Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg. Infect. Dis. 12 (2006) 844-847
66. Toll A., Gallardo F., Ferran M., Gilaberte M., Iglesias M., Gimeno J.L., Rondini S., and Pujol R.M. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin. Exp. Dermatol. 30 (2005) 649-651
67. Torrado E., Fraga A.G., Castro A.G., Stragier P., Meyers W.M., Portaels F., Silva M.T., and Pedrosa J. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect. Immun. 75 (2007) 977-987
68. Uganda Buruli Group. BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). Lancet 1 (1969) 111-115
69. Uganda Buruli Group. Clinical features and treatment of pre-ulcerative Buruli lesions (Mycobacterium ulcerans infection). Report II of the Uganda Buruli Group. Br. Med. J. 2 (1970) 390-393
70. Veitch M.G., Johnson P.D., Flood P.E., Leslie D.E., Street A.C., and Hayman J.A. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol. Infect. 119 (1997) 313-318
71. Walsh G.P., Tan E.V., dela Cruz E.C., Abalos R.M., Villahermosa L.G., Young L.J., Cellona R.V., Nazareno J.B., and Horwitz M.A. The Philippine cynomolgus monkey (Macaca fascicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat. Med. 2 (1996) 430-436
72. Walsh D.S., Meyers W.M., Krieg R.E., and Walsh G.P. Transmission of Mycobacterium ulcerans to the nine-banded armadillo. Am. J. Trop. Med. Hyg. 61 (1999) 694-697
73. Walsh D.S., Meyers W.M., Portaels F., Lane J.E., Mongkolsirichaikul D., Hussem K., Gosi P., and Myint K.S. High rates of apoptosis in human Mycobacterium ulcerans culture positive Buruli ulcer skin lesions Am. J. Trop. Med. Hyg. 73 (2005) 410-415
74. Walsh D.S., dela Cruz E.C., Abalos R.M., Tan E.V., Walsh G.P., Portaels F., and Meyers W.M. Clinical and histological features of skin lesions in a cynomolgus monkey experimentally infected with Mycobacterium ulcerans (Buruli ulcer) by intradermal inoculation. Am. J. Trop. Med. Hyg. 76 (2007) 132-134
75. Wansbrough-Jones M., and Phillips R. Buruli ulcer: emerging from obscurity. Lancet 367 (2006) 1849-1858
76. WHO, 2001. The Management of Mycobacterium ulcerans Disease (Buruli Ulcer). World Health Organization, Geneva, WHO/CDS/CPE/GBUI/2001.3.
77. WHO, 2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization, Geneva, WHO/CDS/CPE/GBUI/2004.
78. WHO, 2006. Buruli Ulcer: Prevention of Disability (POD). World Health Organization, Geneva, WHO/CDS/NTD/GBUI/2006.12.
79. WHO. Buruli ulcer progress report, 2004-2008. Wkly Epidemiol. Rec. 83 (2008) 145-154